Home LiteratureArticle Details
PMID: 15219235 Published · epublish English Journal Article

Peritoneal inflammation - A microenvironment for Epithelial Ovarian Cancer (EOC).

Journal of translational medicine ·Vol. 2 ·No. 1 ·2004-06-25 ·Pages 23

Freedman RS, Deavers M, Liu J, Wang E

Abstract

Epithelial ovarian cancer (EOC) is a significant cause of cancer related morbidity and mortality in women. Preferential involvement of peritoneal structures contributes to the overall poor outcome in EOC patients. Advances in biotechnology, such as cDNA microarray, are a product of the Human Genome Project and are beginning to provide fresh opportunities to understand the biology of EOC. In particular, it is now possible to examine in depth, at the molecular level, the complex relationship between the tumor itself and its surrounding microenvironment.This review focuses on the anatomy, physiology, and current immunobiologic research of peritoneal structures, and addresses certain potentially useful animal models. Changes in both the inflammatory and non-inflammatory cell compartments, as well as alterations to the extracellular matrix, appear to be signal events that contribute to the remodeling effects of the peritoneal stroma and surface epithelial cells on tumor growth and spread. These alterations may involve a number of proteins, including cytokines, chemokines, growth factors, either membrane or non-membrane bound, and integrins. Interactions between these molecules and molecular structures within the extracellular matrix, such as collagens and the proteoglycans, may contribute to a peritoneal mesothelial surface and stromal environment that is conducive to tumor cell proliferation and invasion. These alterations need to be examined and defined as possible prosnosticators and as therapeutic or diagnostic targets.

Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Freedman Ralph S
Department of Gynecologic Oncology, The University of Texas M,D, Anderson Cancer Center, Houston, TX, USA. rfreedma@mdanderson.org
Deavers Michael
Liu Jinsong
Wang Ena
References (51)
51 references, click to expand
  1. The organizing principle: microenvironmental influences in the normal and malignant breast.
    Differentiation. 2002 Dec;70(9-10):537-46 PMID: 12492495
  2. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.
    N Engl J Med. 2003 Jan 16;348(3):203-13 PMID: 12529460
  3. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines.
    Am J Pathol. 1997 May;150(5):1723-34 PMID: 9137096
  4. Quantitative analysis of transforming growth factor beta 1 and 2 in ovarian carcinoma.
    Clin Cancer Res. 1999 Sep;5(9):2498-505 PMID: 10499625
  5. In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein.
    Cancer Res. 1994 Feb 15;54(4):1071-6 PMID: 7508819
  6. Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells.
    J Immunol. 1999 Dec 1;163(11):6251-60 PMID: 10570318
  7. Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial.
    J Immunother Emphasis Tumor Immunol. 1994 Oct;16(3):198-210 PMID: 7834119
  8. The dominance of the microenvironment in breast and ovarian cancer.
    Semin Cancer Biol. 2002 Apr;12(2):97-104 PMID: 12027581
  9. A genetically defined model for human ovarian cancer.
    Cancer Res. 2004 Mar 1;64(5):1655-63 PMID: 14996724
  10. Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy.
    J Immunol Methods. 1994 Jan 3;167(1-2):145-60 PMID: 8308273
  11. Pilot study of Flt3 ligand comparing intraperitoneal with subcutaneous routes on hematologic and immunologic responses in patients with peritoneal carcinomatosis and mesotheliomas.
    Clin Cancer Res. 2003 Nov 1;9(14):5228-37 PMID: 14614003
  12. Differential expression of cytokine transcripts in human epithelial ovarian carcinoma by solid tumour specimens, peritoneal exudate cells containing tumour, tumour-infiltrating lymphocyte (TIL)-derived T cell lines and established tumour cell lines.
    Clin Exp Immunol. 1998 May;112(2):172-80 PMID: 9649178
  13. Inflammation and cancer.
    Nature. 2002 Dec 19-26;420(6917):860-7 PMID: 12490959
  14. Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma.
    J Biol Chem. 2002 Jul 5;277(27):24584-93 PMID: 11978786
  15. Genetic alterations in the peritumoral stromal cells of malignant and borderline epithelial ovarian tumors as indicated by allelic imbalance on chromosome 3p.
    Int J Cancer. 2004 Mar 20;109(2):247-52 PMID: 14750176
  16. Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma.
    Clin Cancer Res. 2002 Dec;8(12):3686-95 PMID: 12473577
  17. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes.
    Trends Immunol. 2002 Nov;23(11):549-55 PMID: 12401408
  18. Expression of interleukin-6 and monocyte chemoattractant protein-1 by peritoneal sub-mesothelial cells during abdominal operations.
    J Pathol. 2004 Jan;202(1):34-40 PMID: 14694519
  19. Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis.
    Perit Dial Int. 1992;12(1):14-27 PMID: 1347465
  20. Sensing the environment: a historical perspective on integrin signal transduction.
    Nat Cell Biol. 2002 Apr;4(4):E83-90 PMID: 11944041
  21. Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure.
    J Natl Cancer Inst. 1997 Apr 2;89(7):480-7 PMID: 9086004
  22. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer.
    Am J Obstet Gynecol. 1991 Apr;164(4):1038-42; discussion 1042-3 PMID: 2014824
  23. Effects of interleukin-6 on in vitro cell attachment, migration and invasion of human ovarian carcinoma.
    Anticancer Res. 1997 Jan-Feb;17(1A):337-42 PMID: 9066674
  24. Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma.
    Int J Cancer. 1996 Nov 4;68(3):276-84 PMID: 8903466
  25. Interleukin (IL)-6 and IL-10 induce decorin mRNA in endothelial cells, but interaction with fibrillar collagen is essential for its translation.
    J Biol Chem. 2004 May 14;279(20):21266-70 PMID: 15016829
  26. The role of cytokines in both the normal and malignant ovary.
    Endocr Relat Cancer. 1999 Mar;6(1):93-107 PMID: 10732792
  27. The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer.
    J Clin Invest. 1995 May;95(5):2391-6 PMID: 7738202
  28. Peritoneal and subperitoneal stroma may facilitate regional spread of ovarian cancer.
    Clin Cancer Res. 2005 Jan 1;11(1):113-22 PMID: 15671535
  29. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer.
    Cancer Res. 2002 Oct 15;62(20):5930-8 PMID: 12384559
  30. Cytotoxic T cell clones isolated from ovarian tumor-infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells.
    J Immunol. 1991 Mar 1;146(5):1700-7 PMID: 1704404
  31. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Clin Cancer Res. 2000 Jun;6(6):2268-78 PMID: 10873077
  32. A cytokine profile of normal and malignant ovary.
    Cytokine. 1996 Jul;8(7):578-85 PMID: 8891439
  33. Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer.
    Cancer. 1993 Oct 15;72(8):2433-40 PMID: 8402460
  34. Tumor-associated macrophages: a molecular perspective.
    Int Immunopharmacol. 2002 Jul;2(8):1045-54 PMID: 12349942
  35. Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings.
    Obstet Gynecol. 1999 Jan;93(1):21-4 PMID: 9916949
  36. IL-6 secretion by human peritoneal mesothelial and ovarian cancer cells.
    Cytokine. 1995 Aug;7(6):542-7 PMID: 8580370
  37. Serum evaluation of interleukin 6 in ovarian cancer patients.
    Gynecol Oncol. 1997 Jul;66(1):27-30 PMID: 9234916
  38. Molecular basis of renal fibrosis.
    Pediatr Nephrol. 2000 Dec;15(3-4):290-301 PMID: 11149129
  39. Selective depletion of fibroblasts preserves morphology and the functional integrity of peritoneum in transgenic mice with peritoneal fibrosing syndrome.
    Kidney Int. 2003 Nov;64(5):1722-32 PMID: 14531805
  40. Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer.
    J Immunol. 1994 Mar 1;152(5):2393-400 PMID: 8133050
  41. A phase I-II trial of intraperitoneal cisplatin and alpha-interferon in patients with persistent epithelial ovarian cancer.
    Gynecol Oncol. 1991 Mar;40(3):237-43 PMID: 2013446
  42. Lineage-negative human leukocyte antigen-DR+ cells with the phenotype of undifferentiated dendritic cells in patients with carcinoma of the abdomen and pelvis.
    Clin Cancer Res. 1998 Mar;4(3):799-809 PMID: 9533550
  43. E2F4/5 and p107 as Smad cofactors linking the TGFbeta receptor to c-myc repression.
    Cell. 2002 Jul 12;110(1):19-32 PMID: 12150994
  44. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival.
    Cancer. 2004 Jul 1;101(1):3-27 PMID: 15221985
  45. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system.
    Cancer Cell. 2002 Feb;1(1):53-62 PMID: 12086888
  46. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies.
    J Cell Biol. 1997 Apr 7;137(1):231-45 PMID: 9105051
  47. The dual role of IL-10.
    Trends Immunol. 2003 Jan;24(1):36-43 PMID: 12495723
  48. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
    Cancer Res. 2001 Jun 15;61(12):4766-72 PMID: 11406550
  49. Chemokine/chemokine receptor nomenclature.
    Cytokine. 2003 Jan 7;21(1):48-9 PMID: 12668160
  50. Cadherin switching in ovarian cancer progression.
    Int J Cancer. 2003 Aug 20;106(2):172-7 PMID: 12800191
  51. The expression of decorin in human ovarian tumors.
    Clin Cancer Res. 2002 Jun;8(6):1754-60 PMID: 12060613
Article Info
Journal
Journal of translational medicine
Abbr.
J Transl Med
ISSN
1479-5876
Published
2004-06-25
Epub
2004-00-25
Pages
23
Language
English
Region
England
NLM ID
101190741
PMCID
PMC459521
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com